Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes.
The main aim of pharmaceutical technology research is the design of successful formulations for effective therapy, taking into account several issues including therapeutic requirements and patient compliance. In this regard, several achievements have been reported with colloidal carriers, in particular with lipid nanoparticles, due to their unique physicochemical properties. For several years these carriers have been showing potential success for several administration routes, namely oral, dermal, parenteral, and, more recently, for pulmonary and brain targeting. The present chapter provides a review of the use of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) to modify the release profile and the pharmacokinetic parameters of active pharmaceutical ingredients (APIs) incorporated in these lipid matrices, aiming to modify the API bioavailability, either upwards or downwards depending on the therapeutic requirement. Definitions of the morphological characteristics, surface properties, and polymorphic structures will also be given, emphasizing their influence on the incorporation parameters of the API, such as yield of production, loading capacity, and encapsulation efficiency.
Souto
Eliana B
EB
Faculty of Health Sciences, Fernando Pessoa University, Rua Carlos da Maia, 296, P-4200-150, Porto, Portugal. eliana@ufp.edu.pt
Müller
Rainer H
RH
D000818:Animals; D001682:Biological Availability; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D053758:Nanoparticles; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000378:metabolism; D013678:Technology, Pharmaceutical / Q000379:methods
D004337:Drug Carriers; D008055:Lipids; D004364:Pharmaceutical Preparations